已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Recent updates on bispecific T-cell engager (BiTE) antibodies in relapsed and refractory multiple myeloma.

医学 多发性骨髓瘤 内科学 耐火材料(行星科学) 抗体 肿瘤科 免疫学 物理 天体生物学
作者
Abdul Rafae,Ahsan Wahab,Hamid Ehsan,Joshua Christy,Tabinda Saleem,Emad Kandah,Rabia Ali,Mustafa Nadeem Malik,Sundas Ali,Sara Saeed,Faiz Anwer
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (15_suppl): e20034-e20034 被引量:8
标识
DOI:10.1200/jco.2021.39.15_suppl.e20034
摘要

e20034 Background: Bispecific T-cell engager (BiTE) antibodies are currently being studied for various hematological malignancies including relapsed and refractory multiple myeloma (RRMM). BiTE antibodies that target CD3 on T cells and antigens GPRC5D, BCMA or FcRH5 on myeloma cells are being studied in RRMM patients (pts). Methods: A comprehensive literature search was done on Pubmed, Embase, and Cochrane. The data presented in various conferences (ASH, ASCO) were also included. Results: Six clinical trials are currently evaluating anti-BCMA, anti CD3 BiTE in RRMM. Madduri et al. reported ORR of 39% in 49 pts treated with REGN5458 an anti BCMA and CD3 BiTE antibody. Grafall et. al reported an ORR of 73% with Teclistamab at 1500µg/kg SC. Harrison et al. reported ORR of 83% in 9 pts treated with 9mg of AMG 701. Lesokhin et al. reported an ORR of 33% among 18 RRMM pts at all dose levels and ORR of 75%. at dose level of 215μg/kg weekly (n=4), and 360 μg/kg weekly (n=4). Rodriguez et al. reported an ORR of 80% among 15 RRMM pts treated with TNB-383B at the dose of 40-60mg IV every 3 weeks. Topp et al reported an ORR of 70% among 10 pts treated with AMG420/BI-836909 at MTD of 400µg/d. Chari et al reported results of Talquetamab which targets GPRC5D which showed an ORR of 66% in 55 evaluable pts. ORR at RP2D (405 µg/kg SC) was 69% in 19 pts treated at this dose. Cohen et al reported results on BFCR4350A, an anti FcRH5 BiTE which showed an ORR of 53% at dose ≥3.6/20mg Q3W. Cytokine release syndrome (CRS) is a serious side effect of BiTE antibodies and was reported in 39%, 64%, 65%, 61%, 45%, 38%, 54% and 76% in studies by Madduri et al, Grafall et al., Harrison et al., Lesokhin et al., Rodriguez et al., Topp et al., Chari et al., and Cohen et al., respectively. Most of the CRS cases were grade 1-2 and resolved either by themselves or required treatment with tocilizumab and steroids. Other most common side effects are reported in table. Conclusions: The most recent data on BiTE antibodies in RRMM has shown promising results with good tolerability. However, the trials are ongoing and a longer follow up is needed.[Table: see text]
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Rs完成签到,获得积分10
2秒前
3秒前
Owen的应助被DW采纳,获得10
4秒前
今我来思完成签到 ,获得积分10
4秒前
赵绡洁发布了新的文献求助10
4秒前
米诺发布了新的文献求助10
4秒前
LSQ完成签到,获得积分10
6秒前
传奇3的应助被无聊的寒香采纳,获得10
6秒前
蓝桉完成签到 ,获得积分10
7秒前
五嶽完成签到 ,获得积分10
8秒前
10秒前
共享精神的应助被vc采纳,获得10
10秒前
orixero的应助被nancyruoxi采纳,获得30
11秒前
12秒前
12秒前
端庄的香薇完成签到,获得积分10
12秒前
陈博士发布了新的文献求助10
13秒前
13秒前
14秒前
一丁雨完成签到,获得积分10
14秒前
合适山灵完成签到,获得积分10
15秒前
米诺完成签到,获得积分10
15秒前
16秒前
一丁雨发布了新的文献求助10
16秒前
Maestro_S的应助被DW采纳,获得30
17秒前
白晓涵完成签到 ,获得积分10
17秒前
山海发布了新的文献求助10
18秒前
大熊发布了新的文献求助10
19秒前
风雪征途完成签到,获得积分20
19秒前
AdamJie发布了新的文献求助30
19秒前
榆庭完成签到,获得积分10
20秒前
秋秋发布了新的文献求助20
21秒前
风雪征途发布了新的文献求助10
21秒前
明亮的依珊完成签到,获得积分10
22秒前
橘子完成签到,获得积分10
24秒前
迷路飞凤完成签到,获得积分10
25秒前
默笙完成签到 ,获得积分10
30秒前
Dyying完成签到,获得积分10
30秒前
31秒前
充电宝的应助被大熊采纳,获得10
31秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184889
求助须知:如何正确求助?哪些是违规求助? 9573836
关于积分的说明 21833242
捐赠科研通 7782263
什么是DOI,文献DOI怎么找? 3434429
关于科研通互助平台的介绍 2558581
邀请新用户注册赠送积分活动 2481082